Helping solve the challenges of hospital initiation

Sotalol IV (sotalol hydrochloride injection 15 mg/mL for intravenous use) offers flexibility, control, and speed, so patients may avoid inconvenient hospitalization days.

Indication and usage.

Sotalol hydrochloride for intravenous use is an antiarrhythmic agent indicated for substitution for oral sotalol in patients who are unable to take sotalol orally.

  • Use for the maintenance of normal sinus rhythm in patients with history of highly symptomatic atrial fibrillation/flutter
  • Use for the treatment of documented life-threatening ventricular arrhythmias

See below for pediatric dosing guidance.

Recommended per Guidelines

The American Heart Association (AHA) recommends use of Sotalol IV in its Guidelines for Cardiopulmonary Resuscitation & Emergency Cardiovascular Care.1

Important Safety Information

WARNING: LIFE-THREATENING PROARRHYTHMIA See full prescribing information for complete boxed warning.
  • Sotalol can cause life-threatening ventricular tachycardia associated with QT interval prolongation
  • Do not initiate sotalol therapy if the baseline QTc is longer than 450 ms
  • If the QT interval prolongs to 500 ms or greater, the dose must be reduced, the duration of the infusion prolonged or the drug discontinued
  • Patient should be hospitalized in a facility that can provide cardiac resuscitation and continuous electrocardiographic monitoring
  • Adjust the dosing interval based on creatinine clearance

The future of Sotalol IV: New FDA pathway for accelerated approval

AltaThera was recently selected by the FDA for a new regulatory program. This program allows for an accelerated pathway to develop new dosing for adult atrial fibrillation.

Pediatric dosing: patients <2 years of age

Sotalol IV dose should be reduced by a factor that depends on age.